MediPal : Notice Regarding Decision on Matters Concerning Acquisition of Treasury Stock and Cancellation of Treasury Stock
May 14, 2024 at 02:17 am
Share
May 14, 2024
MEDIPAL HOLDINGS CORPORATION
Representative: Shuichi Watanabe, Representative Director, President and CEO
Code number: 7459 (Prime Market, Tokyo Stock Exchange)
Contact: Yuji Sakon,
Managing Director, General Manager of Administration Division
Tel: +81-3-3517-5171
Notice Regarding Decision on Matters Concerning Acquisition of Treasury Stock
and Cancellation of Treasury Stock
At a meeting of the Bord of Directors held on May 14, 2024, MEDIPAL HOLDINGS CORPORATION ("MEDIPAL") resolved matters related to the acquisition of treasury stock pursuant to Article 459, Paragraph 1 of the Companies Act and the MEDIPAL's Articles of Incorporation. And MEDIPAL resolved to cancel the treasury stock to be acquired through this resolution pursuant to Article 178 of the Companies Act. Details follow below.
Reasons for the acquisition and the cancellation of treasury stock To improve capital efficiency through shareholder returns.
Details of the matters concerning the acquisition
(1)
Class of stock to be acquired
Common stock
Total number of shares to be
Up to 2,500,000 shares
(2)
(1.2% of the total number of common stock issued
acquired
(excluding treasury stock))
(3)
Total acquisition cost
Up to 5 billion yen
(4)
Period of acquisition
From May 15, 2024 to August 30, 2024
(5)
Method of acquisition
Market buying on the Tokyo Stock Exchange
3. Details of the matters concerning the cancellation
(1)
Class of stock to be cancelled
Common stock
(2)
Total number of shares to be
The number corresponding to all of the treasury stock
cancelled
acquired through 2 above
(3)
Cancellation date
Implemented by September 30, 2024 after completion of the
treasury stock acquired through 2 above
Reference
Status of treasury stock holding (as of April 30, 2024)
Total number of shares outstanding
210,016,973 Shares
(excluding treasury stock)
Total number of treasury shares
11,274,369 Shares
# # #
The English version of this document is a translation of the Japanese original and is provided for information purposes only. While reasonable efforts have been made to provide an accurate translation, no liability is assumed by MEDIPAL HOLDINGS CORPORATION for any errors, omissions, or ambiguities in the translation. In the event of any inconsistency or conflict between the English version and the Japanese original, the Japanese original shall prevail.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Medipal Holdings Corporation published this content on
14 May 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
14 May 2024 06:16:35 UTC.
MEDIPAL HOLDINGS CORPORATION engages in the wholesale of pharmaceutical products, cosmetics and daily miscellaneous goods. The Company operates in three segments. The Ethical Pharmaceutical Wholesale segment is involved in the wholesale of pharmaceutical products, medical equipment and test reagents, the distribution and planning of specialty drugs, the construction of medical material database and others. The Cosmetics, Daily Product and General Medicine Wholesale segment is engaged in the wholesale of cosmetics, daily miscellaneous goods and general pharmaceuticals. The Veterinary Medicine and Food Processing Raw Materials Wholesale segment is engaged in the wholesale of veterinary products, food additives and food raw materials. The Company is also involved in the provision of cleaning services, the management and operation of logistics centers, the provision of manpower dispatching services and others.